LivaNova

LivaNova PLC is a publicly traded medical device company formed from the strategic merger of Sorin Group and Cyberonics, unifying cardiovascular and neuromodulation expertise. Its mission is to change the trajectory of lives through two core platforms: VNS Therapy™ for neurological disorders and the Essenz™ Perfusion System for cardiopulmonary surgery. The company has established strong commercial footprints in both therapeutic areas and is advancing its pipeline to expand indications and integrate digital health capabilities. LivaNova's strategy hinges on leveraging deep clinical evidence, driving operational excellence, and pursuing disciplined innovation to address significant unmet medical needs.

LivaNova's technology is built on two core platforms: 1) Implantable Vagus Nerve Stimulation (VNS) Therapy for neuromodulation in epilepsy and depression, and 2) the integrated Essenz™ Perfusion System for cardiopulmonary support during cardiac surgery.

In neuromodulation, LivaNova competes with NeuroPace's RNS System and DBS therapies for epilepsy, and with DBS and other neurostimulation devices for depression. In cardiopulmonary, it faces off against large, established players like Getinge (Maquet) and Terumo, competing on system integration, safety, and total cost of ownership.